ReNeuron’s Dec’20 £17.5m raise now means the Group is sufficiently funded through key upcoming milestones for its lead hRPC candidate and the exosome platform – mitigating a previous pivotal issue. 2021 could promise to be the critical year for the Group, with the potential to unlock value from its programmes well beyond its current modest market value. We refresh our forecasts post yesterday’s analyst briefing, and reiterate our positive stance.
07 Jan 2021
Funded beyond key clinical milestones
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Funded beyond key clinical milestones
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
07 Jan 2021 -
Author:
Edward Thomason -
Pages:
3
ReNeuron’s Dec’20 £17.5m raise now means the Group is sufficiently funded through key upcoming milestones for its lead hRPC candidate and the exosome platform – mitigating a previous pivotal issue. 2021 could promise to be the critical year for the Group, with the potential to unlock value from its programmes well beyond its current modest market value. We refresh our forecasts post yesterday’s analyst briefing, and reiterate our positive stance.